Journal article

Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease

Steven Bozinovski, Anastasia Hutchinson, Michelle Thompson, Lochlan MacGregor, James Black, Eleni Giannakis, Anne-Sophie Karlsson, Roger Silvestrini, David Smallwood, Ross Vlahos, Louis B Irving, Gary P Anderson

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | AMER THORACIC SOC | Published : 2008

Abstract

RATIONALE: Much of the total disease burden and cost of chronic obstructive pulmonary disease (COPD) is associated with acute exacerbations of COPD (AECOPD). Serum amyloid A (SAA) is a novel candidate exacerbation biomarker identified by proteomic screening. OBJECTIVES: To assess SAA as a biomarker of AECOPD. METHODS: Biomarkers were assessed (1) cross-sectionally (stable vs. AECOPD; 62 individuals) and (2) longitudinally with repeated measures (baseline vs. AECOPD vs. convalescence; 78 episodes in 37 individuals). Event severity was graded (I, ambulatory; II, hospitalized; III, respiratory failure) based on consensus guidelines. MEASUREMENTS AND MAIN RESULTS: Presumptively newly acquired pa..

View full abstract